Review Article

Pathogenesis of Abdominal Aortic Aneurysms: Role of Nicotine and Nicotinic Acetylcholine Receptors

Zong-Zhuang Li and Qiu-Yan Dai

Department of Cardiovascular Medicine, First People’s Hospital, Shanghai Jiao-Tong University School of Medicine (SJTUSM), Shanghai 200080, China

Correspondence should be addressed to Qiu-Yan Dai, qiuyand@yahoo.com

Received 30 November 2011; Revised 11 January 2012; Accepted 11 January 2012

Academic Editor: François Mach

Copyright © 2012 Z.-Z. Li and Q.-Y. Dai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammation, proteolysis, smooth muscle cell apoptosis, and angiogenesis have been implicated in the pathogenesis of abdominal aortic aneurysms (AAAs), although the well-defined initiating mechanism is not fully understood. Matrix metalloproteinases (MMPs) such as MMP-2 and -9 and other proteinases degrading elastin and extracellular matrix are the critical pathogenesis of AAAs. Among the risk factors of AAAs, cigarette smoking is an irrefutable one. Cigarette smoke is practically involved in various aspects of the AAA pathogenesis. Nicotine, a major alkaloid in tobacco leaves and a primary component in cigarette smoke, can stimulate the MMPs expression by vascular SMCs, endothelial cells, and inflammatory cells in vascular wall and induce angiogenesis in the aneurysmal tissues. However, for the inflammatory and apoptotic processes in the pathogenesis of AAAs, nicotine seems to be moving in just the opposite direction. Additionally, the effects of nicotine are probably dose dependent or associated with the exposure duration and may be partly exerted by its receptors—nicotinic acetylcholine receptors (nAChRs). In this paper, we will mainly discuss the pathogenesis of AAAs involving inflammation, proteolysis, smooth muscle cell apoptosis and angiogenesis, and the roles of nicotine and nAChRs.

1. Introduction

Abdominal aortic aneurysms (AAAs) usually occur naturally in the infrarenal part in the human abdominal aorta. In men aged 65–80 years, the prevalence of AAAs is between 4% and 8% and approximately six times greater in men than women [1, 2]. An AAA is a permanent localized dilatation of the abdominal aorta (beginning at the level of the diaphragm and extending to its bifurcation into the left and right common iliac arteries in human) that exceeds the normal diameter by 50%, or >3 cm [3].

The primary risk factors of AAAs include family history, smoking, increasing age, male gender, central obesity, and low HDL-cholesterol levels [2, 4]. Hypertension (systolic BP > 160 mmHg, diastolic BP > 95 mmHg) is associated with the AAA risk, but only in women [5]. Diabetes, a well-defined risk factor for atherosclerosis, has been shown to be protective against the AAAs [6–8].

Historically, the AAAs have been considered as a focal manifestation of the advanced atherosclerosis [9]. However, this conventional theory has been challenged by recent evidences: an AAA was a local representation of a systemic disease of the vasculature [10]. There was a lower incidence of AAAs in the individuals suffering from diabetes mellitus that ordinarily considered as the risk equivalent of atherosclerosis [6–8]. The inflammatory cells were recruited into the different sites: the outer media and adventitia of aneurysma, and the intima and subendothelium of atheroma [11–13].

Three key processes contribute to the AAA phenotype: inflammation, proteolysis, and smooth muscle cell (SMC) apoptosis [2]. On the basis of the loss of extracellular matrix especially elastin and accumulation of proteolytic enzymes in the aneurysmal tissues, proteolysis has been regarded as the critical pathogenesis of AAAs [14]. The extracellular matrix degradation by both predominant proteolytic enzymes...
MMP-2 and -9, which synthesized and released mainly by the vascular SMCs and infiltrating inflammatory cells such as macrophages, contribute to the anoikis of vascular SMCs. The vascular SMC apoptosis is another critical pathogenesis of AAAs. It has been demonstrated that the decreasing number of the medial vascular SMCs in the vascular wall from the AAAs patients was relevant to apoptosis [15–21]. Degradation of elastin and apoptotic cell death of the medial vascular SMCs destroys the aortic wall integrity, weaken the wall tensile strength, consequently facilitate the development of AAAs. The inflammatory responses in vascular wall play a pivotal role in the MMPs expression and vascular SMC apoptosis. Conversely, the apoptosis and antigen exposure as a result of the extracellular matrix degradation are also likely to contribute to the immune and/or inflammatory responses. Therefore, the initiating factors of AAAs remain mysterious. The mechanism underlying the inflammatory responses in the outer media and adventitia of the vascular wall remains to be well defined. Recent researches have shown that the increased angiogenesis in all layers of the aneurysmal wall is associated with inflammatory responses and related to aneurysmal rupture [22–25].

Cigarette smoking is the irrefutable risk factor of AAAs. It has recently been demonstrated by Stolle et al. [26] that cigarette mainstream smoke enhanced the AAA formation in Ang II-treated apolipoprotein E-deficient mice as a result of the increased proteolytic activity of MMPs. Nicotine, a major alkaloid in tobacco leaves and a primary component in cigarette smoke, plays its pathophysiological roles partly through its receptor—nicotinic acetylcholine receptors (nAChRs). In this paper, we will mainly discuss the pathogenesis of AAAs involving inflammation, proteolysis, vascular SMC apoptosis and angiogenesis, and the roles of nicotine and nAChRs. We made the highlighted change according to the list of references.

2. Nicotine and nAChRs

Nicotine is a principal tobacco alkaloid occurring to the extent of about 1.5% by weight in commercial cigarette tobacco and comprising about 95% of the total alkaloid content. The nicotine in tobacco is largely the levorotary (S)-nicotine, only 0.1 to 0.6% of total nicotine content is dextrorotary (R)-nicotine [27].

There are two major types of cholinergic receptors: the muscarinic and the nicotinic. The endogenous ligand, acetylcholine stimulates both receptor types, while the exogenous one, nicotine, preferentially stimulates nAChRs. The nAChRs were firstly identified in excitable cells, but later were identified in many other cell types including vascular and immune/inflammatory cells. There are 17 distinct isomers (α1–α10, β1–β4, δ1, γ1, and ε) of the subunits, which form homeric or heteromeric channels. Among the subtypes, the “muscle-type” nAChRα1, the five polypeptide subunits (α1, β1, δ1, and ε in a 2:1:1:1:1 ratio), and the homomeric “CNS-type”, α7-nAChRs, have been identified in a variety of non-neuromuscular cell types such as vascular ECs, vascular SMCs, smooth muscle specific α-actin positive myofibroblasts, T lymphocytes, and macrophages [28–32]. It has been shown that nAChRs, particularly “muscle-type” nAChRs α1 and homomeric CNS-type α7 nAChRs had participated in the pathological processes of atherosclerosis and angiogenesis [33].

3. Nicotine, nAChRs, and Inflammation in AAAs

Inflammation plays a pivotal role in the formation and progression of AAAs and aneurysm rupture [34, 35]. The inflammatory cells including T, B lymphocytes, neutrophils, macrophages, and MCs mostly are recruited into the outer media and adventitia of the aneurysmal wall [13, 22, 24, 36, 37]. Periaortic adipose tissue may also be one of the resident sites of inflammatory cells. Police et al. [38] have demonstrated that the increased number of macrophages in periaortic adipose tissue surrounding the abdominal aortas of Ang II-infused obese mice was associated with the enhanced AAA formation. The inflammatory cells release not only photolytic enzymes to degrade elastin and other matrix proteins, but also inflammatory and chemotactic factors to recruit more inflammatory cells and stimulate the vascular SMC synthetic phenotype by autocrine/paracrine. In previous studies, macrophages have been frequently examined and shown its indispensability in AAAs. T lymphocytes are not indispensable in the AAAs induced by Ang II in apolipoprotein E-deficient male mice, although which play a dominant role in atherosclerosis [39, 40]. Recently, the role of MCs in the AAA development has also been paid more attention by scientists. The specific granule contents from MCs are very important for the inflammatory cell recruitment, pro-MMP and renin-angiotensin system activation, angiogenesis, and vascular SMC apoptosis [36, 41].

It has been shown by few studies that nicotine played a proinflammatory role in vasculature in vivo and in vitro. Two in vitro experiments have demonstrated that nicotine promoted the VCAM-1 and ICAM-1 expression on human coronary artery endothelial cells and human umbilical vein endothelial cells [42, 43]. In another study, chronic (during 90 days) nicotine exposure enhanced the production of pro-inflammatory cytokines such as TNFα, Interleukin 1β (IL-1β) by macrophages and upregulates the mRNA expression level of VCAM-1, cyclooxygenase-2 (COX-2), and platelet-derived growth factor β (PDGF-β) in the aortas from low-density lipoprotein receptor-deficient mice [44]. It has been well known that VCAM-1 and ICAM-1 were the key mediators of the inflammatory cell migration and infiltration into vascular wall [45]. Nevertheless, more evidences have demonstrated the anti-inflammatory role of nicotine via nAChRs, that is, the so-called cholinergic anti-inflammatory pathway [46–48]. If a hypothesis that “nicotine can stimulate formation and progression of AAAs through inflammation” is true, it is the best explanation that the prolonged exposure to nicotine may induce desensitization and changes in the expression of nAChRs and thus the beneficial effects of nicotine through its receptors may be halted? [49, 50]. It must be conceded that the AAAs were usually detected in the older people with a longer smoking history [49].
Moreover, it has been indicated by some investigations that the inflammatory mediators including COX-2 and 5-lipoxygenase (5-LO) were also associated with the development of AAAs.

COX-2, a limiting enzyme converting arachidonic acid into prostaglandin, plays an important role in the inflammatory diseases. In human AAAs, the increased expression of COX-2 is associated with the augmented angiogenesis [51]. King et al. demonstrated the increased expression of COX-2 and the upregulated synthesis of PGE₂ selectively in the aortic aneurismatic tissues by exposure to Ang II. The selective COX-2 inhibitor, celecoxib, decreased the incidence and severity of Ang II-induced AAAs in apolipoprotein E-deficient mice and C57BL/6J mice [52]. The above studies indicate that the increased COX-2 expression is one of the pathogenesis of AAA formation. It has been implied by limited studies that nicotine could stimulate the COX-2 expression likely through nAChRs. In human umbilical vein endothelial cells, nicotine increases the COX-2, ICAM-1, and PGE₂ expression through NF-kappaB activation which mediated by nAChRs [53]. In gastric cancer, nicotine stimulates the COX-2 expression to trigger tumor cell invasion and angiogenesis through the VEGF activation, which subsequently modulates the MMP activity and plasmogen activators expression [54].

Activation of the 5-LO pathway contributes to the biosynthesis of proinflammatory leukotriene mediators in macrophages, MCs, and other inflammatory cells [55]. 5-LO plays a role in promoting the AAA formation induced by an atherosclerotic diet in apolipoprotein E-deficient mice. 5-LO-positive macrophages localize in the adventitia of the diseased mouse and human arteries in the areas of neovascularization and constitute a major component of the aortic aneurysms. 5-LO deficiency attenuates the aortic aneurysms and reduces the aortic MMP-2 activity and diminished plasma macrophage inflammatory protein-1α (MIP-1α) [56]. It has been recently shown that the mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-LO, 5-LO-activating protein (FLAP), and LTC₄ synthase (LTC₄S), were significantly increased in the aneurysmal wall from the human abdominal aneurysms. 5-LO, FLAP, and LTC₄S proteins express in the media and adventitia and localize in the areas rich in inflammatory cells including macrophages, neutrophils, and MCs. Exogenous LTD₄ increased the MMP-2 and -9 release [57]. Houard et al. have similarly demonstrated that, in the aneurysmal wall of the human abdominal aortas, the leukotriene pathway mainly localized in the macrophage-rich adventitial areas [58]. It has been recently indicated that nicotine could induce the 5-LO expression in colon neoplasm [59]. A hypothesis: “smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway.” Had been proposed by Takagi and Umemoto [60] in 2005, but to date, it remains to be demonstrated.

Taken together, it has been demonstrated by compelling evidences that the inflammation in vascular wall is one of the pathogenesis of AAAs. Mediated by the inflammatory cells such as macrophages and MCs and inflammatory mediators including VCAM-1, ICAM-1, COX-2, and 5-LO, the inflammatory responses have a preference for the outer media and adventitia of the aneurysmal wall. Currently, the notion that nicotine promotes the AAA formation by its receptor nAChRs is still not supported by robust evidences. Fortunately, in our recent animal experiment, the AAAs have been successfully induced by both nicotine and Ang II in the older C57BL/6J mice, accompanied with the MC degranulation in the adventitia of the abdominal aortas. Maybe, it will point out a direction for further research.

4. Nicotine, nAChRs, and Proteolysis Induced by MMPs in AAAs

Although the abundant connective tissue proteinases including MMPs (MMP-1, -2, -3, -9, -12, and -13), serine proteinases (tissue-type plasminogen activator (t-PA); urokinase-type plasminogen activator (u-PA); plasmin; and neutrophil elastase), as well as cysteine proteinases (cathepsin D, K, L, and S) [61] have been described in the human AAA tissues, the most attentions have been kept on the members of the matrix metalloproteinase family [24, 62–65]. Previous studies have focused on the 92-kD (MMP-9; gelatinase B) and 72-kD (MMP-2; gelatinase A) gelatinase/type IV collagenase, both most prominent elastolytic enzymes secreted by the AAA tissues in organ culture and in vivo, which are expressed by macrophages, vascular SMCs, fibroblasts, or ECs, most often in the areas adjacent to the infiltrated inflammatory cells [62, 66–70]. Therefore, it has been shown a close relationship between MMPs and inflammatory responses in the aneurysmal tissues.

The MMPs are a group of zinc-mediated enzymes present in the extracellular matrix. It is a fundamental pathogenesis of AAAs that the increased MMPs in vascular wall degrade all kinds of extracellular matrix proteins, particularly elastin [14, 71]. The MMPs are inhibited by the specific endogenous TIMPs, which comprise a family of four protease inhibitors: TIMP-1, -2, -3 and -4. An imbalance in the proteolytic equilibrium between MMPs and TIMPs is a significant factor of the AAA formation [72]. Elastin and collagens type I/III keep the integrity and elasticity of vascular wall, and resist stretch. Under normal conditions, the content of the proteins keeps balance between degradation and synthesis. But in fact, the balance is principally maintained by the collagen metabolism, because elastin is synthesized and deposited in the early childhood and no further significant synthesis occurs in adult life [73]. The content of collagens type I/III increases compensatively in the early stage of the disease, while decreases dramatically in the advanced stage. Degradation of elastin and loss of collagens during the advanced stage destroy the wall integrity and weaken the wall tensile strength, which promotes the development and rupture of AAAs. It is supposed that the degradation of elastin is likely to exert a more significant role in the initiating process of AAAs.

It has been recently demonstrated that cigarette mainstream smoke could enhance the proteolytic activity of MMPs including MMP-2 and -9 induced by Ang II and accelerate both formation and severity of AAAs in the
hypertensive apolipoprotein E-deficient mice, [26] while cigarette smoke extract significantly downregulated TIMP-3 in aortic endothelial cells [74]. Similarly, nicotine increases the MMPs (especially MMP-2 and -9) expression and activities in the vascular wall components including ECs, vascular SMCs and infiltrating inflammatory cells such as neutrophils and macrophages, [54, 75–80] and decreases the expression of TIMP-1, -3, and -4 in osteoblasts [81]. Moreover, the endogenic ligand of nicotine, α7-nAChRs, is also involved in the MMP-2 and -9 upregulation in human retinal microvascular endothelial cells [80].

Taken together, nicotine and/or its ligand α7-nAChRs have been involved in the synthesis and release of proteolytic ingredients MMP-2 and -9 and decreased the TIMPs expression in vivo and in vitro, thus very likely to be involved in the pathogenesis of AAAs.

5. Nicotine, nAChRs, and Medial Vascular SMC Apoptosis in AAAs

Histological examinations of both animal and human experimental AAAs have revealed a paucity of medial vascular SMCs in these specimens which are associated with the SMC apoptosis [15–21]. Vascular SMCs synthesize and release the extracellular matrix proteins including collagens, elastin, glycoproteins, and proteoglycans to provide the mechanical integrity to the vascular wall. In the aortic media, collagens are primarily synthesized by vascular SMCs. Theoretically, a paucity of medial vascular SMCs caused by apoptotic cell death, can reduce the synthesis of extracellular matrix proteins and collagens turnover, eventually attenuate the mechanical properties of the aortic wall and result in the formation and complications of AAAs. Henderson et al. have demonstrated that vascular SMC apoptosis, macrophages, and T lymphocytes coexisted in the aortic media and accompanied by the upregulation of proapoptotic initiators, such as Fas/FasL in the human AAA segments obtained from the patients undergoing open repair [15]. Recently, Yamanouchi et al. [82] firstly reported the direct links between medial vascular SMC apoptosis and pathogenesis of AAAs. In an Ang II-induced aneurysm model in apolipoprotein E-deficient mice, a novel caspase inhibitor Q-VD-OPh, inhibited apoptosis by blocking activation of caspases, drastically reduced the number of infiltrating macrophages and CD3+ T cells and remarkably decreased the interleukin-6 level as well as the elastase activity. These findings suggested that inhibition of apoptosis may attenuate the aneurysm formation not only by preventing the vascular SMC depletion but also by affecting the vascular inflammation and matrix degradation.

In in vitro studies, cigarette smoke extract causes apoptosis of aortic SMCs, human umbilical vein endothelial cells, pulmonary artery endothelial cells, and aortic endothelial cells from human and rodent animals [83–86]. Beyond our expectations, as a major ingredient of cigarette smoke, nicotine inhibits apoptosis of aortic SMCs and ECs through nAChRs in several investigations [87, 88]. Anyway, the viewpoint that nicotine is involved in the formation and progression of AAAs through apoptotic mechanism seems to be not supported by existing evidences.

6. Nicotine Stimulates Angiogenesis through α7-nAChRs in AAAs

Angiogenesis is the new blood vessel formation from pre-existing blood vessels and is a prominent feature in both atherosclerosis and AAAs [23, 25, 89]. In 1996, Thompson et al. [23] had demonstrated that the density of the newly formed vessels was increased in all layers of the aneurysmal wall compared with the control samples. The degree of neovascularization is correlated with the extent of the inflammatory infiltration. Angiogenesis is associated with the inflammatory responses in the aneurysmal wall and accelerate the aneurysm rupture [22–25].

Usually, angiogenic stimuli (e.g., hypoxia or inflammatory cytokines) may induce the expression and release of angiogenic growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). These growth factors stimulate the proliferation of ECs in the existing vasculature and migration through the tissue to form new endothelialized channels [90, 91]. Almost all subunits of nAChRs are expressed on ECs, whereas the most abundant receptor subunit is α7-nAChRs [92]. Accumulated evidences have shown that, through excitable α7-nAChRs on the plasma membrane of vascular SMCs or ECs, nicotine could stimulate the proliferation and migration of ECs, increase the VEGF and FGF release by vascular SMCs and ECs and promote angiogenesis [29, 54, 79, 93–96]. Moreover, the VEGF receptor and α7-nAChRs appear to mediate the distinct but interdependent pathways of angiogenesis [97].

Neovascularization is not the exclusive characteristic of AAAs, which also exists in the atherosclerotic lesion, chronic ischemia, tumor and other illnesses. Therefore, angiogenesis may not be a causative but a "contributing to progression and rupture of aneurysm" factor in the pathological process of AAAs.

It has been recently implied by a chronic nicotine exposure experiment in an hindlimb ischemic mice model that chronic nicotine exposure impaired the angiogenic response to ischemia mediated partly by downregulation of the vascular α7-nAChRs, as well as by a reduction in plasma VEGF level [98]. However, because the researches did not assess the functional measures of limb perfusion, the conclusion remains to be further confirmed.

7. Conclusion

It is irrefutable that cigarette smoking is the principal risk factor for AAAs, but as a primary ingredient of cigarette smoke, nicotine, which has role in AAAs is undefined. The increased MMPs expression and degradation of all kinds of extracellular matrix proteins, particularly elastin, in the aneurysmal wall, has been demonstrated by compelling evidences, and nicotine may be involved in the process. The angiogenesis stimulated by nicotine may be the important factor for the progression or rupture of AAAs rather
than the causative factor. Inflammation and apoptosis of vascular SMCs, two important pathogenesis of AAAs, are seemingly irrelevant to nicotine. Whether nicotine is the key component in cigarette smoke promoting the formation and progression of AAAs remains equivocal. In a chronic nicotine exposure experiment during 90 days, the inflammatory responses in the aorta are enhanced [44]. It may be explained as the desensitization and changes in the expression of nAChRs and thus the beneficial effects of nicotine through its receptors may be halted [49, 50]. Moreover, the adverse effects of nicotine through desensitization and changes in the expression of nAChRs and thus the beneficial effects of nicotine through its receptors may be halted [49, 50].

Today, cigarette smoking remains a serious social problem. Nicotine replacement therapy is often used [49, 93, 99]. To today, cigarette smoking remains a serious social problem. Nicotine replacement therapy is often used [49, 93, 99].

Abbreviations

AAA: Abdominal aortic aneurysm
MMP: Matrix metalloproteinase
TIMP: Tissue inhibitors of metalloproteinase
HDL: High density lipoprotein
nAChRs: Nicotinic acetylcholine receptors
SMC: Smooth muscle cell
EC: Endothelial cell
MC: Mast cell
CNS: Central nervous system
AngII: Angiotensin II
VCAM-1: Vascular cellular adhesion molecule-1
ICAM-1: Intercellular adhesion molecule-1
COX-2: Cyclooxygenase-2
5-LO: 5-lipoxygenase
FLAP: 5-LO-activating protein
PGEl: Prostaglandin E1
MIP-1α: Macrophage inflammatory protein-1α
LTC4S: Leukotriene C4 synthase
LTD4: Leukotriene D4
VEGF: Vascular endothelial growth factor
FGF: Fibroblast growth factor.

Acknowledgment

This work was supported by Grants (no. 09JC1412300) from the Shanghai Committee of Science and Technology, China.

References

[1] R. A. P. Scott, S. G. Bridgewater, and H. A. Ashton, “Randomized clinical trial of screening for abdominal aortic aneurysm in women,” British Journal of Surgery, vol. 89, no. 3, pp. 283–285, 2002.
[2] I. M. Nordon, R. J. Hinchliffe, I. M. Loftus, and M. M. Thompson, “Pathophysiology and epidemiology of abdominal aortic aneurysms,” Nature Reviews Cardiology, vol. 8, no. 2, pp. 92–102, 2011.
[3] K. W. Johnston, R. B. Rutherford, M. D. Tilson, D. M. Shah, L. Hollier, and J. C. Stanley, “Suggested standards for reporting on arterial aneurysms,” Journal of Vascular Surgery, vol. 13, no. 3, pp. 452–458, 1991.
[4] J. Golledge, J. Muller, A. Daugherty, and P. Norman, “Abdominal aortic aneurysm: pathogenesis and implications for management,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 12, pp. 2605–2613, 2006.
[5] S. H. Forsdahl, K. Singh, S. Solberg, and B. K. Jacobsen, “Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the tromsø study, 1994 2001,” Circulation, vol. 119, no. 16, pp. 2202–2208, 2009.
[6] S. Shantikumar, R. Ajjian, K. E. Porter, and D. J. A. Scott, “Diabetes and the abdominal aortic aneurysm,” European Journal of Vascular and Endovascular Surgery, vol. 39, no. 2, pp. 200–207, 2010.
[7] J. Golledge, M. Karan, C. S. Moran et al., “Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions,” European Heart Journal, vol. 29, no. 5, pp. 663–672, 2008.
[8] N. Miyama, M. M. Dua, J. J. Yeung et al., “Hyperglycemia limits experimental aortic aneurysm progression,” Journal of Vascular Surgery, vol. 52, no. 4, pp. 975–983, 2010.
[9] M. I. Patel, D. T. A. Hardman, C. M. Fisher, and M. Appleberg, “Current views on the pathogenesis of abdominal aortic aneurysms,” Journal of the American College of Surgeons, vol. 181, no. 4, pp. 371–382, 1995.
[10] I. Nordon, R. Brar, J. Taylor, R. Hinchliffe, I. M. Loftus, and M. M. Thompson, “Evidence from cross-sectional imaging indicates abdominal but not thoracic aortic aneurysms are local manifestations of a systemic dilating diathesis,” Journal of Vascular Surgery, vol. 50, no. 1, pp. 171–176.e1, 2009.
[11] A. Rudijanto, “The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis,” Acta medica Indonesiana, vol. 39, no. 2, pp. 86–93, 2007.
[12] T. Miyake, M. Aoki, H. Nakashima et al., “Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFκB and ets using chimeric decoy oligonucleotides in a rabbit model,” Gene Therapy, vol. 13, no. 8, pp. 695–704, 2006.
[13] T. Tsuruda, J. Kato, K. Hatakeyama et al., “Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm,” Circulation Research, vol. 102, no. 11, pp. 1368–1377, 2008.
[14] K. M. Mata, P. S. Prudente, F. S. Rocha et al., “Combining two potential causes of metalloproteinase secretion causes abdominal aortic aneurysms in rats: a new experimental model,” International Journal of Experimental Pathology, vol. 92, no. 1, pp. 26–39, 2011.
[15] E. L. Henderson, Y. J. Geng, G. K. Sukhova, A. D. Whittemore, J. Knox, and P. Libby, “Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms,” Circulation, vol. 99, no. 1, pp. 96–104, 1999.
[16] A. López-Candales, D. R. Holmes, S. Liao, M. J. Scott, S. A. Wickline, and R. W. Thompson, “Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms,” American Journal of Pathology, vol. 150, no. 3, pp. 993–1007, 1997.
[17] L. J. Walton, I. J. Franklin, T. Bayston et al., “Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms,” Circulation, vol. 100, no. 1, pp. 48–54, 1999.
[18] L. Zhang, J. Schmidt, E. Ryschich, H. Schumacher, and J. R. Allenberg, “Increased apoptosis and decreased density of medial smooth muscle cells in human abdominal aortic aneurysms,” Journal of Vascular Surgery, vol. 35, no. 3, pp. 544–548, 2001.
aneurysms,” *Chinese Medical Journal*, vol. 116, no. 10, pp. 1549–1552, 2003.

[19] V. L. Rowe, S. L. Stevens, T. T. Reddick et al., “Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas,” *Journal of Vascular Surgery*, vol. 31, no. 3, pp. 567–576, 2000.

[20] R. W. Thompson, S. Liao, and J. A. Curci, “Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms,” *Coronary Artery Disease*, vol. 8, no. 10, pp. 623–631, 1997.

[21] I. Sinha, A. P. Sinha-Hikim, K. K. Hannawa et al., “Mitochondrial-dependent apoptosis in experimental rodent abdominal aortic aneurysms,” *Surgery*, vol. 138, no. 4, pp. 806–811, 2005.

[22] J. Satta, Y. Soini, M. Mosorin, and T. Juvonen, “Angiogenesis is associated with mononuclear inflammatory cells in abdominal aortic aneurysms,” *Annales Chirurgiae et Gynaecologiae*, vol. 87, no. 1, pp. 40–42, 1998.

[23] M. M. Thompson, L. Jones, A. Nasim, R. D. Sayers, and P. R. F. Bell, “Angiogenesis in abdominal aortic aneurysms,” *European Journal of Vascular and Endovascular Surgery*, vol. 11, no. 4, pp. 464–469, 1996.

[24] N. Diehm, S. Di Santo, T. Schauff et al., “Severe structural damage of the seemingly non-diseased infrarenal aortic aneurysm neck,” *Journal of Vascular Surgery*, vol. 48, no. 2, pp. 423–434, 2008.

[25] E. Choke, G. W. Cockerill, J. Dawson et al., “Increased angiogenesis at the site of abdominal aortic aneurysm rupture,” *Annals of the New York Academy of Sciences*, vol. 1085, pp. 315–319, 2006.

[26] K. Stolle, A. Berges, M. Lietz, S. Lebrun, and T. Wallerath, “Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice,” *Toxicology Letters*, vol. 199, no. 3, pp. 403–409, 2010.

[27] J. Hukkanen, P. Jacob, and N. L. Benowitz, “Metabolism and disposition kinetics of nicotine,” *Pharmacological Reviews*, vol. 57, no. 1, pp. 79–115, 2005.

[28] S. Razani-Boroujerdi, R. T. Boyd, M. I. Davila-Garcia et al., “T cells express α7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response,” *Journal of Immunology*, vol. 179, no. 5, pp. 2889–2898, 2007.

[29] J. C. F. Wu, A. Chruscinski, V. A. De Jesus Perez et al., “Cholinergic modulation of angiogenesis: role of the 7 nicotinic acetylcholine receptor,” *Journal of Cellular Biochemistry*, vol. 108, no. 2, pp. 433–446, 2009.

[30] G. Zhang, A. L. Marshall, A. L. Thomas et al., “In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis,” *Atherosclerosis*, vol. 215, no. 1, pp. 34–42, 2011.

[31] G. Zhang, K. A. Kernan, A. Thomas et al., “A novel signaling pathway: fibroblast nicotinic receptor α1 binds urokinase and promotes renal fibrosis,” *Journal of Biological Chemistry*, vol. 284, no. 42, pp. 29050–29064, 2009.

[32] J. P. Cooke and Y. T. Ghebremariam, “Endothelial nicotinic acetylcholine receptors and angiogenesis,” *Trends in Cardiovascular Medicine*, vol. 18, no. 7, pp. 247–253, 2008.

[33] J. Lee and J. P. Cooke, “The role of nicotine in the pathogenesis of atherosclerosis,” *Atherosclerosis*, vol. 215, no. 2, pp. 281–283, 2011.

[34] V. Treska, J. Kocova, L. Boudova et al., “Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm,” *Cytokines, Cellular and Molecular Therapy*, vol. 7, no. 3, pp. 91–97, 2002.

[35] D. J. Parry, H. S. Al-Barjas, L. Chappell, S. T. Rashid, R. A. S. Ariens, and D. J. A. Scott, “Markers of inflammation in men with small abdominal aortic aneurysm,” *Journal of Vascular Surgery*, vol. 52, no. 1, pp. 145–151, 2010.

[36] J. Swedenborg, M. I. Mäyränäkki, and P. T. Kovanen, “Mast cells: Important players in the orchestrated pathogenesis of abdominal aortic aneurysms,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 4, pp. 734–740, 2011.

[37] W. L. Chan, N. Pejnovic, T. V. Liew, and H. Hamilton, “Predominance of Th2 response in human abdominal aortic aneurysm; mistaken identity for IL-4-producing NK and NKT cells?” *Cellular Immunology*, vol. 233, no. 2, pp. 109–114, 2005.

[38] S. B. Police, S. E. Thatcher, R. Charnigo, A. Daugherty, and L. A. Cassis, “Obesity promotes inflammation in periaortic adipose tissue and angiotensin ii-induced abdominal aortic aneurysm formation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 10, pp. 1458–1464, 2009.

[39] H. A. Ōuchi, F. Kristo, D. L. Rateri et al., “Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice,” *Atherosclerosis*, vol. 211, no. 2, pp. 399–403, 2010.

[40] Y. Wang, H. Ait-Outella, O. Herbin et al., “TGF-β activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice,” *Journal of Clinical Investigation*, vol. 120, no. 2, pp. 422–432, 2010.

[41] S. Takai, D. Jin, and M. Miyazaki, “New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage,” *Journal of Pharmacological Sciences*, vol. 113, no. 4, pp. 301–309, 2010.

[42] P. Cirillo, M. Pacileo, S. De Rosa et al., “HMGCoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells,” *Journal of Vascular Research*, vol. 44, no. 6, pp. 460–470, 2007.

[43] G. Albaugh, E. Bellavance, L. Strande, S. Heinburger, C. W. Hewitt, and J. B. Alexander, “Nicotine induces mononuclear leukocyte adhesion and expression of adhesion molecules, VCAM and ICAM, in endothelial cells in vitro,” *Annals of Vascular Surgery*, vol. 18, no. 3, pp. 302–307, 2004.

[44] P. P. Lau, L. Li, A. J. Merched, A. L. Zhang, K. W. S. Ko, and L. Chan, “Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor−/− mice,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 1, pp. 143–149, 2006.

[45] R. Haverslag, G. Pasterkamp, and I. E. Hoefer, “Targeting adhesion molecules in cardiovascular disorders,” *Cardiovascular and Hematological Disorders—Drug Targets*, vol. 8, no. 4, pp. 252–260, 2008.

[46] H. Yoshikawa, M. Kurokawa, N. Ozaki et al., “Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of L-kb phosphorylation and nuclear factor-kb transcriptional activity through nicotinic acetylcholine receptor α7,” *Clinical and Experimental Immunology*, vol. 146, no. 1, pp. 116–123, 2006.

[47] X. Wang, Z. Yang, B. Xue, and H. Shi, “Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance,” *Endocrinology*, vol. 152, no. 3, pp. 836–846, 2011.

[48] N. Sharentuya, T. Tomimatsu, K. Mimura et al., “Nicotine suppresses interleukin–6 production from vascular endothelial cells: a possible therapeutic role of nicotine for preeclampsia,” *Reproductive Sciences*, vol. 17, no. 6, pp. 556–563, 2010.
[49] P. Balakumar and J. Kaur, "Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?" *Pharmacological Research*, vol. 60, no. 5, pp. 361–368, 2009.

[50] C. L. Gentry and R. J. Lukas, "Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure," *Current Drug Targets. CNS and Neurological Disorders*, vol. 1, no. 4, pp. 359–385, 2002.

[51] K. S. Chapple, D. J. Parry, S. McKenzie, K. A. MacLennan, P. Jones, and D. J. A. Scott, "Cyclooxygenase-2 expression and its association with increased angiogenesis in human abdominal aortic aneurysms," *Annals of Vascular Surgery*, vol. 21, no. 1, pp. 61–66, 2007.

[52] V. L. King, D. B. Trivedi, J. M. Gitlin, and C. D. Loftin, "Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotsin II-induced abdominal aortic aneurysm formation in mice," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 5, pp. 1137–1143, 2006.

[53] Y. Zhou, Z. X. Wang, M. P. Tang et al., "Nicotine induces cyclooxygenase-2 and prostaglandin E2 expression in human umbilical vein endothelial cells," *International Immunopharmacology*, vol. 10, no. 4, pp. 461–466, 2010.

[54] V. Y. Shin, W. K. K. Wu, K. M. Chu et al., "Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated infection and angiogenesis in gastric cancer," *Molecular Cancer Research*, vol. 3, no. 11, pp. 607–615, 2005.

[55] C. D. Funk, R. Y. Cao, L. Zhao, and A. J. R. Habenicht, "Is there a role for the macrophage 3-lipoxygenase pathway in aortic aneurysm development in apolipoprotein E-deficient mice?" *Annals of the New York Academy of Sciences*, vol. 1085, pp. 151–160, 2006.

[56] L. Zhao, M. P. W. Moos, R. Gräbler et al., "The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm," *Nature Medicine*, vol. 10, no. 9, pp. 966–973, 2004.

[57] A. Di Gennaro, D. Wagsäter, M. I. Måyránpää et al., "Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 49, pp. 21093–21097, 2010.

[58] X. Houard, V. Ollivier, L. Louedec, J. B. Michel, and M. Bäck, "Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus," *EASEB Journal*, vol. 23, no. 5, pp. 1376–1383, 2009.

[59] Y. N. Ye, E. S. L. Liu, V. Y. Shin, W. K. K. Wu, J. C. Luo, and C. H. Cho, "Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway," *Journal of Pharmacology and Experimental Therapeutics*, vol. 308, no. 1, pp. 66–72, 2004.

[60] H. Takagi and T. Umemoto, "Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway," *Medical Hypotheses*, vol. 64, no. 6, pp. 1117–1119, 2005.

[61] K. Shimizu, R. N. Mitchell, and P. Libby, "Inflammation and cellular immune responses in abdominal aortic aneurysms," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 5, pp. 987–994, 2006.

[62] K. M. Newman, Y. Ogata, A. M. Malon et al., "Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm," *Arteriosclerosis and Thrombosis*, vol. 14, no. 8, pp. 1315–1320, 1994.

[63] K. M. Newman, A. M. Malon, R. D. Shin, J. V. Scholes, W. G. Ramey, and M. D. Tilson, "Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources," *Connective Tissue Research*, vol. 30, no. 4, pp. 265–276, 1994.

[64] E. Irizarry, K. M. Newman, R. H. Gandhi et al., "Demonstration of interstitial collagenase in abdominal aortic aneurysm disease," *Journal of Surgical Research*, vol. 54, no. 6, pp. 571–574, 1993.

[65] J. M. Reilly, C. M. Brophy, and M. D. Tilson, "Characterization of an elastase from aeurysmal aorta which degrades intact elastic, aneurysm," *Annals of Vascular Surgery*, vol. 6, no. 6, pp. 499–502, 1992.

[66] R. W. Thompson, D. R. Holmes, R. A. Mertens et al., "Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aeurysm- infiltrating macrophages," *Journal of Clinical Investigation*, vol. 96, no. 1, pp. 318–326, 1995.

[67] W. D. McMillan, B. K. Patterson, R. R. Keen, V. P. Shively, M. Capollone, and W. H. Pearce, "In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aeurysmal, occlusive, and normal aorta," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 15, no. 8, pp. 1139–1144, 1995.

[68] T. Freestone, R. J. Turner, A. Coady, D. J. Higman, R. M. Greenhalgh, and J. T. Powell, "Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 15, no. 8, pp. 1145–1151, 1995.

[69] W. D. McMillan, B. K. Patterson, R. R. Keen, and W. H. Pearce, "In situ localization and quantification of seventy-two-kilodalton type IV collagenase in aeurysmal, occlusive, and normal aorta," *Journal of Vascular Surgery*, vol. 22, no. 3, pp. 295–305, 1995.

[70] V. Davis, R. Persidskaia, L. Baca-Regen et al., "Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 18, no. 10, pp. 1625–1633, 1998.

[71] W. B. Keeling, P. A. Armstrong, P. A. Stone, D. F. Bandyk, and M. L. Shames, "An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms," *Vascular and Endovascular Surgery*, vol. 39, no. 6, pp. 457–464, 2005.

[72] J. D. Raffetto and R. A. Khalil, "Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease," *Biochemical Pharmacology*, vol. 75, no. 2, pp. 346–359, 2008.

[73] R. B. Rucker and D. Tinker, "Structure and metabolism of arterial elastin," *International Review of Experimental Pathology*, vol. 17, pp. 1–47, 1977.

[74] V. Lemaître, A. J. Dobó, and J. D’Armiento, “Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling,” *Toxicological Sciences*, vol. 123, no. 2, pp. 542–549, 2011.

[75] A. L. B. Jacob-Ferreira, A. C. T. Paíei, S. B. Cau et al., "Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine," *European Journal of Pharmacology*, vol. 627, no. 1–3, pp. 216–222, 2010.

[76] B. K. Nordskog, A. D. Blix, W. T. Morgan, W. R. Fields, and G. M. Hellmann, "Matrix-degrading and pro-inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate," *Cardiovascular Toxicology*, vol. 3, no. 2, pp. 101–117, 2003.

[77] M. Keepes, J. Pelisek, S. Seidl et al., "Inflammation infiltrates and neovessels are relevant sources of MMPs in abdominal aortic aneurysm wall," *Pathobiology*, vol. 76, no. 5, pp. 243–252, 2009.
M. Raveendran, J. Wang, D. Senthil et al., “Endogenous nitric oxide activation protects against cigarette smoking induced apoptosis in human endothelial cells,” *Journal of Vascular Surgery*, vol. 24, no. 6, pp. 927–935, 1996.

A. M. Dom, A. W. Buckley, K. C. Brown et al., “The α7-nicotinic acetylcholine receptor and MMP-2/9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells,” *Investigative Ophthalmology & Visual Science*, vol. 52, no. 7, pp. 4428–4438, 2011.

T. Katono, T. Kawato, N. Tanabe et al., “Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts,” *Archives of Oral Biology*, vol. 54, no. 2, pp. 146–155, 2009.

D. Yamanouchi, S. Morgan, K. Kato, J. Lengfeld, F. Zhang, and B. Liu, “Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 4, pp. 702–707, 2010.

M. Raveendran, J. Wang, D. Senthil et al., “Endogenous nitric oxide activation protects against cigarette smoking induced apoptosis in endothelial cells,” *FEBS Letters*, vol. 579, no. 3, pp. 733–740, 2005.

R. Aldonyte, E. T. Hutchinson, B. Jin et al., “Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro,” *COPD: Journal of Chronic Obstructive Pulmonary Disease*, vol. 5, no. 3, pp. 153–162, 2008.

J. Wang, D. E. L. Wilcken, and X. L. Wang, “Cigarette smoke activates caspase-3 to induce apoptosis of human umbilical venous endothelial cells,” *Molecular Genetics and Metabolism*, vol. 72, no. 1, pp. 82–88, 2001.

C. L. Hsu, Y. L. Wu, G. J. Tang, T. S. Lee, and Y. R. Kou, “Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: role of heme oxygenase-1,” *Pulmonary Pharmacology and Therapeutics*, vol. 22, no. 4, pp. 286–296, 2009.

A. Cucina, A. Fuso, P. Coluccia, and A. Cavallaro, “Nicotine inhibits apoptosis and stimulates proliferation in aortic smooth muscle cells through a functional nicotinic acetylcholine receptor,” *Journal of Surgical Research*, vol. 150, no. 2, pp. 227–235, 2008.

A. Hakki, H. Friedman, and S. Pross, “Nicotine modulation of apoptosis in human coronary artery endothelial cells,” *International Immunopharmacology*, vol. 2, no. 10, pp. 1403–1409, 2002.

R. L. Silverstein and R. L. Nachman, “Angiogenesis and atherosclerosis: the mandate broadens,” *Circulation*, vol. 100, no. 8, pp. 783–785, 1999.

P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” *Nature*, vol. 407, no. 6801, pp. 249–257, 2000.

T. Pralhad, S. Madhusudan, and K. Rajendrakumar, “Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases,” *Journal of Pharmacy and Pharmacology*, vol. 55, no. 8, pp. 1045–1053, 2003.

Y. Wang, E. F. R. Pereira, A. D. J. Maus et al., “Human bronchial epithelial and endothelial cells express α7 nicotinic acetylcholine receptors,” *Molecular Pharmacology*, vol. 60, no. 6, pp. 1201–1209, 2001.